
    
      Participants who were in the active arm in the double blind part and those who have completed
      OLE part in the parent study, will continue receive open-label gantenerumab 510 mg
      sub-cutaneously (SC) every 2 weeks (Q2W). Participants who are naive to gantenerumab
      treatment will be required to undergo the 3 step uptitration scheme as in the parent study
      before receiving target dose of open label gantenerumab.
    
  